利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.066 秒)

    Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
    6.
    发明授权
    Cadherin-17 as diagnostic marker and therapeutic target for liver cancer 有权
    钙粘蛋白-17作为肝癌的诊断标志物和治疗靶标

    公开(公告)号：US09207242B2

    公开(公告)日：2015-12-08

    申请号：US12569386

    申请日：2009-09-29

    申请人： John Moon Ching Luk ,  Nikki Pui Yue Lee ,  Lingxiao Liu ,  Ronnie Tung Ping Poon ,  Sheung Tat Fan

    发明人： John Moon Ching Luk ,  Nikki Pui Yue Lee ,  Lingxiao Liu ,  Ronnie Tung Ping Poon ,  Sheung Tat Fan

    IPC分类号： G01N33/574 ,  C07K16/28 ,  C07K16/30

    CPC分类号： G01N33/57438 ,  C07K16/28 ,  C07K16/30 ,  G01N33/57488

    摘要： Compositions and methods for diagnosing, treating and/or preventing cancers characterized by CDH17 overexpression based on the detection of CDH17 or the use of CDH17 as a target for therapeutic intervention or prophylactic intervention are provided. Methods for diagnosing and/or monitoring liver cancers using the expressing of CDH17 involve detecting and/or quantitating the CDH17 protein or encoding nucleic acids (DNA or RNA) in a biological sample such as urine from the subject. Methods for treating liver cancers using CDH17 as a target and of sensitizing cells with aberrant expression of CDH17 have also been developed. The methods include suppression or knockdown of the expression of CDH17 by administering an effective amount of a CDH17 inhibitor.

    摘要翻译： 提供用于诊断，治疗和/或预防基于CDH17检测或CDH17作为治疗干预或预防性干预的靶标的CDH17过表达的特征的癌症的组合物和方法。 使用表达CDH17诊断和/或监测肝癌的方法涉及检测和/或定量生物样品（例如来自受试者的尿液）的CDH17蛋白或编码核酸（DNA或RNA）。 已经开发了使用CDH17作为靶标治疗肝癌和使CDH17异常表达的细胞致敏的方法。 所述方法包括通过施用有效量的CDH17抑制剂来抑制或击倒CDH17的表达。

    Methods and compositions for treatment of endotoxin-mediated pro-inflammatory responses
    7.
    发明授权
    Methods and compositions for treatment of endotoxin-mediated pro-inflammatory responses 有权
    用于治疗内毒素介导的促炎反应的方法和组合物

    公开(公告)号：US07960338B2

    公开(公告)日：2011-06-14

    申请号：US12502548

    申请日：2009-07-14

    申请人： John Moon Ching Luk ,  Kwong Fai Wong ,  Ronnie Tung Ping Poon ,  Sheung Tat Fan

    发明人： John Moon Ching Luk ,  Kwong Fai Wong ,  Ronnie Tung Ping Poon ,  Sheung Tat Fan

    IPC分类号： A01N37/18

    CPC分类号： C07K16/2845 ,  A61K2039/505 ,  C07K2317/622

    摘要： Bacterial lipopolysaccharide (LPS) in systemic circulation triggers deleterious super-inflammatory response, which is key pathogenesis of many disorders like gram-negative sepsis and necrotizing enterocolitis. No effective therapeutic interventions are currently available for protection of patients against mortality. Disclosed are methods and therapeutic agents that ablate the biological toxicity of LPS in circulation (Integrin Peptide), and abrogate leukocyte infiltration into lung and liver and suppress adhesion molecule expression (Integrin Peptide and Anti-CD18 βA scFv). These therapeutic agents can be used alone, or in combination for treatment of endotoxin-mediated pro-inflammatory responses, particularly in cases of acute sepsis and necrotizing enterocolitis.

    摘要翻译： 全身循环中的细菌脂多糖（LPS）引起有害的超炎症反应，这是许多疾病如革兰氏阴性败血症和坏死性小肠结肠炎的关键发病机制。 目前没有有效的治疗干预措施来保护患者免受死亡。 公开了消除LPS在循环中的生物毒性（Integrin Peptide）的方法和治疗剂，并且消除白细胞浸润到肺和肝中并抑制粘附分子表达（Integrin Peptide and Anti-CD18＆bgr; A scFv）。 这些治疗剂可以单独使用或组合用于治疗内毒素介导的促炎症反应，特别是在急性败血症和坏死性小肠结肠炎的情况下。

    METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTOXIN-MEDIATED PRO-INFLAMMATORY RESPONSES
    8.
    发明申请
    METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTOXIN-MEDIATED PRO-INFLAMMATORY RESPONSES 有权
    用于治疗内毒素介导的炎症反应的方法和组合物

    公开(公告)号：US20100008925A1

    公开(公告)日：2010-01-14

    申请号：US12502548

    申请日：2009-07-14

    申请人： John Moon Ching Luk ,  Kwong Fai Wong ,  Ronnie Tung Ping Poon ,  Sheung Tat Fan

    发明人： John Moon Ching Luk ,  Kwong Fai Wong ,  Ronnie Tung Ping Poon ,  Sheung Tat Fan

    IPC分类号： A61K39/395 ,  C07K16/18 ,  C07K14/00 ,  A61P31/04

    CPC分类号： C07K16/2845 ,  A61K2039/505 ,  C07K2317/622

    摘要： Bacterial lipopolysaccharide (LPS) in systemic circulation triggers deleterious super-inflammatory response, which is key pathogenesis of many disorders like gram-negative sepsis and necrotizing enterocolitis. No effective therapeutic interventions are currently available for protection of patients against mortality. Disclosed are methods and therapeutic agents that ablate the biological toxicity of LPS in circulation (Integrin Peptide), and abrogate leukocyte infiltration into lung and liver and suppress adhesion molecule expression (Integrin Peptide and Anti-CD18 βA scFv). These therapeutic agents can be used alone, or in combination for treatment of endotoxin-mediated pro-inflammatory responses, particularly in cases of acute sepsis and necrotizing enterocolitis.

    摘要翻译： 全身循环中的细菌脂多糖（LPS）引起有害的超炎症反应，这是许多疾病如革兰氏阴性败血症和坏死性小肠结肠炎的关键发病机制。 目前没有有效的治疗干预措施来保护患者免于死亡。 公开了消除LPS在循环中的生物毒性（Integrin Peptide）的方法和治疗剂，并且消除了白细胞浸润到肺和肝中并抑制粘附分子表达（Integrin Peptide和Anti-CD18 betaA scFv）。 这些治疗剂可以单独使用或组合用于治疗内毒素介导的促炎症反应，特别是在急性败血症和坏死性小肠结肠炎的情况下。

    CADHERIN-17 AS DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR LIVER CANCER
    9.
    发明申请
    CADHERIN-17 AS DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR LIVER CANCER 有权
    CADHERIN-17作为诊断标记和肝癌治疗目标

    公开(公告)号：US20100092978A1

    公开(公告)日：2010-04-15

    申请号：US12569386

    申请日：2009-09-29

    申请人： Moon Ching John Luk ,  Pui Yue Nikki Lee ,  Lingxiao Liu ,  Tung Ping Ronnie Poon ,  Sheung Tat Fan

    发明人： Moon Ching John Luk ,  Pui Yue Nikki Lee ,  Lingxiao Liu ,  Tung Ping Ronnie Poon ,  Sheung Tat Fan

    IPC分类号： C12Q1/68 ,  G01N33/53 ,  C12N5/02 ,  C07K16/00 ,  C07H21/02 ,  C07H21/00

    CPC分类号： G01N33/57438 ,  C07K16/28 ,  C07K16/30 ,  G01N33/57488

    摘要： Compositions and methods for diagnosing, treating and/or preventing cancers characterized by CDH17 overexpression based on the detection of CDH17 or the use of CDH17 as a target for therapeutic intervention or prophylactic intervention are provided. Methods for diagnosing and/or monitoring liver cancers using the expressing of CDH17 involve detecting and/or quantitating the CDH17 protein or encoding nucleic acids (DNA or RNA) in a biological sample such as urine from the subject. Methods for treating liver cancers using CDH17 as a target and of sensitizing cells with aberrant expression of CDH17 have also been developed. The methods include suppression or knockdown of the expression of CDH17 by administering an effective amount of a CDH17 inhibitor.

    摘要翻译： 提供用于诊断，治疗和/或预防基于CDH17检测或CDH17作为治疗干预或预防性干预的靶标的CDH17过表达的特征的癌症的组合物和方法。 使用表达CDH17诊断和/或监测肝癌的方法涉及检测和/或定量生物样品（例如来自受试者的尿液）的CDH17蛋白或编码核酸（DNA或RNA）。 已经开发了使用CDH17作为靶标治疗肝癌和使CDH17异常表达的细胞致敏的方法。 所述方法包括通过施用有效量的CDH17抑制剂来抑制或击倒CDH17的表达。

    GEP AND DRUG TRANSPORTER REGULATION, CANCER THERAPY AND PROGNOSIS
    10.
    发明申请
    GEP AND DRUG TRANSPORTER REGULATION, CANCER THERAPY AND PROGNOSIS 审中-公开
    GEP和药物运输管理条例，癌症治疗和预防

    公开(公告)号：US20110280862A1

    公开(公告)日：2011-11-17

    申请号：US13107034

    申请日：2011-05-13

    申请人： Siu Tim Cheung ,  Sheung Tat Fan

    发明人： Siu Tim Cheung ,  Sheung Tat Fan

    IPC分类号： A61K39/395 ,  A61P43/00 ,  C12N5/02

    CPC分类号： C07K16/22 ,  A61K33/24 ,  A61K39/3955 ,  A61K45/06 ,  C07K14/475 ,  A61K2300/00

    摘要： Described herein are methods for manipulating GEP and/or drug transporters (e.g., ABCB5 and/or ABCF1) on a cell, as well as related products. Also described herein are methods for treating cancer cells using GEP and/or drug transporter and/or their binding molecules and suppression thereof. Methods of cancer treatment targeting the GEP and/or drug transporters, alone or in combination with chemotherapy are also described herein. Also provided herein are sets of markers whose expression patterns can be used to differentiate clinical conditions, such as high or low levels of GEP and drug transporters. Based on the levels of GEP and drug transporters, the likelihood of cancer recurrences, drug sensitivity, and prognosis can be determined. Methods of classifying and treating patients based on the prognosis are also provided herein.

    摘要翻译： 本文描述了用于操作细胞上的GEP和/或药物转运蛋白（例如，ABCB5和/或ABCF1）以及相关产品的方法。 本文还描述了使用GEP和/或药物转运蛋白和/或其结合分子及其抑制来治疗癌细胞的方法。 本文还描述了单独或与化学疗法组合靶向GEP和/或药物转运蛋白的癌症治疗方法。 本文还提供了一组标记，其表达模式可用于区分临床条件，例如高水平或低水平的GEP和药物转运蛋白。 基于GEP和药物转运蛋白的水平，可以确定癌症复发的可能性，药物敏感性和预后。 本文还提供了基于预后对患者进行分类和治疗的方法。